Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.

M RuggeriMichele BasileS CorettiC DragoA Cicchetti

Published in: Applied health economics and health policy (2018)

Entecavir and tenofovir are recommended for the treatment of patients with chronic Hepatitis B in the Italian Health System. In particular, tenofovir appeared to be the more cost-effective drug for the management of chronic hepatitis B virus (HBV) infections. These results could help decision makers and clinicians to address their decision when choosing a first-line treatment for the management of people affected by chronic HBV.

Keyphrases

hepatitis b virus
liver failure
antiretroviral therapy
decision making
drug induced
emergency department